Format

Send to

Choose Destination
Expert Rev Proteomics. 2016;13(2):157-83. doi: 10.1586/14789450.2016.1132167. Epub 2016 Jan 22.

Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates.

Author information

1
a Centre d'Immunologie Pierre-Fabre (CIPF) , Saint-Julien-en-Genevois , France.
2
b BioOrganic Mass Spectrometry Laboratory (LSMBO), IPHC, Analytical Sciences Department , Université de Strasbourg , Strasbourg , France.
3
c IPHC, Analytical Sciences Department, CNRS, UMR7178 , Strasbourg , France.

Abstract

Antibody drug conjugates (ADCs) are highly cytotoxic drugs covalently attached via conditionally stable linkers to monoclonal antibodies (mAbs) and are among the most promising next-generation empowered biologics for cancer treatment. ADCs are more complex than naked mAbs, as the heterogeneity of the conjugates adds to the inherent microvariability of the biomolecules. The development and optimization of ADCs rely on improving their analytical and bioanalytical characterization by assessing several critical quality attributes, namely the distribution and position of the drug, the amount of naked antibody, the average drug to antibody ratio, and the residual drug-linker and related product proportions. Here brentuximab vedotin (Adcetris) and trastuzumab emtansine (Kadcyla), the first and gold-standard hinge-cysteine and lysine drug conjugates, respectively, were chosen to develop new mass spectrometry (MS) methods and to improve multiple-level structural assessment protocols.

KEYWORDS:

Antibody-drug-conjugate; IdeS; bioanalysis; brentuximab vedotin; drug-to-antibody ratio; ion mobility MS; mass spectrometry; native MS; trastuzumab emtansine

PMID:
26653789
DOI:
10.1586/14789450.2016.1132167
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center